Compare CUZ & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUZ | BLLN |
|---|---|---|
| Founded | 1958 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | 1994 | 2025 |
| Metric | CUZ | BLLN |
|---|---|---|
| Price | $29.00 | $116.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $28.00 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.2M | 524.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | 0.01 | ★ 0.48 |
| Revenue | ★ $993,816,000.00 | $305,112,000.00 |
| Revenue This Year | $5.61 | $46.29 |
| Revenue Next Year | $4.23 | $30.14 |
| P/E Ratio | $2,890.00 | ★ $241.81 |
| Revenue Growth | 16.00 | ★ 99.97 |
| 52 Week Low | $21.03 | $61.96 |
| 52 Week High | $32.95 | $150.44 |
| Indicator | CUZ | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.